Introduction {#s1}
============

Major depressive disorder (MDD) is present in approximately 20% of patients with coronary heart disease (CHD), including acute coronary syndrome (ACS) patients [@pone.0027671-Rudisch1], [@pone.0027671-Thombs1]. Depression impacts quality of life post-ACS [@pone.0027671-Rumsfeld1], and many studies have linked MDD or depressive symptoms to poor prognosis [@pone.0027671-vanMelle1].

The rate of self-reported antidepressant use increased from approximately 7% to 12% among US adults from 1996 to 2005 [@pone.0027671-Olfson1]. In Europe, just under 4% of respondents from 6 countries surveyed between 2001 and 2003 reported 12-month antidepressant use [@pone.0027671-The1]. The potential for tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) to cause serious and potentially fatal side effects has limited their use in cardiac populations [@pone.0027671-Glassman1], [@pone.0027671-Murray1]. On the other hand, selective serotonin reuptake inhibitors (SSRIs) have generally been accepted as safe in cardiac patients because they appear to lack these side effects [@pone.0027671-Glassman2]--[@pone.0027671-Taylor1]. Several clinical trials have examined the efficacy of SSRIs in cardiac populations [@pone.0027671-Glassman2], [@pone.0027671-OConnor1], [@pone.0027671-Lesprance1]--[@pone.0027671-Pizzi1] and have reported effect sizes that are similar to those from non-cardiac populations [@pone.0027671-Thombs2]--[@pone.0027671-Delisle1]. Concerns have been raised in recent years, however, about previously unrecognized adverse side effects of SSRIs potentially relevant to CHD patients [@pone.0027671-Andrade1]--[@pone.0027671-US1], as well as potentially dangerous interactions between SSRIs and commonly used cardiac medications [@pone.0027671-Tibold1]--[@pone.0027671-Whang1].

No systematic reviews have characterized the rate of antidepressant use or prescription in ACS patients, which was the objective of this review.

Methods {#s2}
=======

Reporting of the study was based on guidelines established by the Meta-analysis of Observational Studies in Epidemiology statement [@pone.0027671-Stroup1].

Data Sources and Searches {#s2a}
-------------------------

Potentially eligible articles were identified from the PubMed, PsycINFO, and CINAHL databases, searched on May 29, 2009. Search strategies ([Supporting Information S1](#pone.0027671.s001){ref-type="supplementary-material"}) were designed to identify articles that reported on ACS patients in association with depression or antidepressant use. In addition, manual searching of 33 cardiology, psychiatry, and general medicine journals ([Supporting Information S2](#pone.0027671.s002){ref-type="supplementary-material"}) was conducted to identify articles published subsequent to the electronic database search (May 1, 2009 to September 30, 2010).

Study Selection {#s2b}
---------------

Eligible articles included published articles of original research in any language that reported point or period prevalence of antidepressant use or prescription in the 12 months prior or subsequent to an ACS, defined as unstable angina, non-ST-elevation myocardial infarction (MI), or ST-elevation MI, for at least 100 patients. Antidepressants included SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), TCAs, MAOIs, and atypical antidepressants. Studies with data on only a single antidepressant class were excluded. Studies with inclusion criteria that required antidepressant use or a condition associated with antidepressant use (e.g., depressive disorders) and studies that utilized antidepressants as part of an intervention were excluded unless they reported data on antidepressant prescription or use for all patients assessed for study eligibility. Non-published studies, studies published in abstract form only, letters, editorials, and case series or case reports were excluded. When multiple articles were published on the same cohort or portions of the same cohort, the article with the most complete data was included. Studies with mixed populations were included if data for ACS patients were reported separately.

Two investigators independently reviewed articles for eligibility. If either deemed an article potentially eligible based on title/abstract review, then a full-text review was completed. Disagreements after full-text review were resolved by consensus of three investigators, including the two reviewers. Non-English articles were evaluated by one investigator with the assistance of a translator. As necessary, authors were contacted to clarify information relevant to determining eligibility.

Data Extraction {#s2c}
---------------

Two investigators independently extracted data from included studies into a standardized spreadsheet with discrepancies resolved via consensus. Extracted data included the study setting (North America, Europe, other), study inclusion/exclusion criteria, sample size, prevalence of antidepressant prescription/use (total and by antidepressant class), method of assessing antidepressant prescription/use, and time period of assessment. [Methods](#s2){ref-type="sec"} of assessment were classified as administrative database, review of medical record, observation of medication containers, and patient self-report. The time period was recorded as the midpoint of the range of years when data were collected. When antidepressant use was assessed at multiple time points for the same patients, the time point closest to the index ACS was used. Authors were contacted as necessary for clarification.

One included article [@pone.0027671-Benazon1] used province-wide administrative data from Ontario, Canada to determine the percentage of post-MI patients aged 65 or older who were prescribed an antidepressant in the first 6 months post-MI. Antidepressant prescriptions were reported on a quarterly basis from the second calendar quarter of 1993 to the first calendar quarter of 2002. Numerical data were provided for the first and last quarters of the study, with scatterplot data provided for other quarters. Original data were no longer available (personal communication, Muhammad Mamdani, May 17, 2010). Therefore, two investigators estimated quarterly prevalence data from the published scatterplot, and all estimates were within 0.1% of each other. For the purposes of the present study, data are presented for one calendar quarter per year (second quarter 1993 through second quarter 2001).

Data Synthesis and Analysis {#s2d}
---------------------------

Included studies were evaluated to determine if there was sufficient clinical and methodological similarity to support a pooled meta-regression of the rate of antidepressant prescription or use over time, factoring in setting (North America versus Europe and other) and method of assessment (administrative data versus self-report or chart review). However, excluding the study by Benazon et al. [@pone.0027671-Benazon1] that provided quarterly data over an approximately 10-year period, there were too few studies overall and not enough coverage across time, setting, and assessment method to reasonably pool all of the data from the other studies with meta-regression. Therefore, a qualitative synthesis was done for all studies in the review and a quantitative meta-analysis for a subset of studies.

Specifically, we determined that there was a sufficient number of studies to assess the association of time and setting with antidepressant prescription or use among studies that ascertained rates using non-administrative data (e.g., self-report or chart review) with the midpoint of data collection from October 1997 or later. There was not enough coverage of studies to extend the analysis prior to October 1997 or to include studies with administrative data.

For this subset of studies, we first performed an overall meta-analysis and then proceeded to fit meta-regressions controlling for region and for time. The I^2^ statistic was used to assess heterogeneity for the meta-analysis [@pone.0027671-Higgins1], and radial and funnel plots were generated to assess model assumptions. The R statistical software was used to analyze the results via the *metafor* library [@pone.0027671-R1], [@pone.0027671-Viechtbauer1]. The main meta-regression model was fit using Restricted Maximum Likelihood estimators with the rate of antidepressant usage as the outcome.

Results {#s3}
=======

Search Results {#s3a}
--------------

The database search yielded 1,619 unique citations ([Figure 1](#pone-0027671-g001){ref-type="fig"}), including 666 selected for full text review and 35 that met inclusion criteria. Of the 35 eligible articles, 12 reported on the same cohort, leaving 23 unique articles for review. One additional eligible article was identified through manual search, resulting in a total of 24 included articles [@pone.0027671-Benazon1], [@pone.0027671-Grunau1]--[@pone.0027671-Wong1].

![Flow Diagram of Study Selection Process.](pone.0027671.g001){#pone-0027671-g001}

Characteristics of Included Studies {#s3b}
-----------------------------------

As shown in [Table 1](#pone-0027671-t001){ref-type="table"}, the 24 included studies reported data on antidepressant prescription or use from April 1993 through December 2005. Data from one published study by Benazon et al. [@pone.0027671-Benazon1] reported antidepressant prescription rates in the 6 months following hospital discharge for patients surviving at least 6 months from the 2^nd^ quarter of 1993 to the 1^st^ quarter of 2002. There were 13 studies from North America, 8 from Europe, and 1 each from Japan, Australia, and New Zealand. As shown in [Table 2](#pone-0027671-t002){ref-type="table"}, only 3 studies used data from administrative databases, including the Benazon et al. study [@pone.0027671-Benazon1]. One study reviewed patients\' medication containers, and 20 used self-report, medical chart review, or a combination of the two. Sample sizes in the 3 studies that used administrative data ranged from 1,637 to 8,887 patients. For other studies, the range was from 126 to 2,509 patients. Of the 24 studies, 15 reported antidepressant prescription or use during the index ACS admission or at discharge, 4 reported pre-admission prescription or use, and 5 studies reported post-ACS prescription or use. One study reported antidepressant use among women aged \<65 years [@pone.0027671-ZimmermannViehoff1], 2 studies did not report gender composition [@pone.0027671-Benazon1], [@pone.0027671-Grunau1], and the rest of the studies included predominantly males (57% to 98%).

10.1371/journal.pone.0027671.t001

###### Characteristics of Studies Included in the Systematic Review.

![](pone.0027671.t001){#pone-0027671-t001-1}

  First Author, Year                                 Country                                              Patients                                                N        \% MI             MeanAge(Years)                           \% Male                              \% White                 Years of Study
  ----------------------------------------------- ------------- -------------------------------------------------------------------------------------------- ------------ ------- ------------------------------------ ------------------------------------- ------------------------------------- ----------------
  Benazon, 2005[a](#nt102){ref-type="table-fn"}      Canada      MI admission, survived ≥6 months postdischarge; ≥65 years; no MI 3 years prior to index MI   1637--2231   100%                    NR                                   NR                                    NR                      1993--2002
  Grunau, 2006                                       Canada                                       MI admission; ≥66 years                                        5559      100%                    NR                                   NR                                    NR                      1994--1995
  Lesperance, 2000                                   Canada                              Unstable angina admission; documented CAD                               430        0%                     62                                   71%                                   NR                      1994--1996
  Parakh, 2008                                         USA                                              MI admission                                             284       100%                    65                                   57%                                   87%                     1995--1996
  Sauer, 2001                                          USA                                    First MI admission; 30--65 years                                   653       100%    52[b](#nt103){ref-type="table-fn"}   68%[b](#nt103){ref-type="table-fn"}                   NR                      1995--1997
  Lauzon, 2003                                       Canada                                             MI admission                                             464       100%    60[c](#nt104){ref-type="table-fn"}   79%[c](#nt104){ref-type="table-fn"}   96%[c](#nt104){ref-type="table-fn"}     1996--1998
  Grace, 2005                                        Canada                                            ACS admission                                             913        53%                    62                                   65%                                   NR                      1997--1999
  Rumsfeld, 2003                                       USA                                             ACS admission                                             1957       50%                    65                                   98%                                   89%                     1998--1999
  Frasure-Smith, 2008                                Canada                                 ACS admission; cardiac catherization                                 804        NR                     60                                   81%                                   NR                      1999--2001
  Corser, 2006                                         USA                                             ACS admission                                             521        NR                     60                                   64%                                   84%                     2002--2003
  Mallik, 2006                                         USA                                              MI admission                                             2361      100%                    61                                   68%                                   NR                      2003--2004
  Grace, 2008                                        Canada                                            ACS admission                                             505        NR                     62                                   77%                                   84%                     2003--2004
  Huffman, 2006                                        USA                                              MI admission                                             131       100%                    62                                   80%                                   NR                      2003--2005
  Zimmermann-Viehoff, 2010                           Sweden                                  Women \<65 years admitted for ACS                                   266        36%                    56                                   0%                                    NR                      1991--1993
  Monster, 2004                                      Denmark                                         First MI admission                                          8887      100%                    72                                   62%                                   NR                      1994--2002
  Dickens, 2007                                        UK                                               MI admission                                             507       100%    59[d](#nt105){ref-type="table-fn"}   71%[d](#nt105){ref-type="table-fn"}   95%[d](#nt105){ref-type="table-fn"}     1997--1999
  Kaptein, 2006                                    Netherlands                                          MI admission                                             475       100%                    61                                   81%                                   NR                      1997--2000
  Pitzalis, 2001                                      Italy                                       MI admission \<70 years                                        128       100%    54[e](#nt106){ref-type="table-fn"}   86%[e](#nt106){ref-type="table-fn"}                   NR                      1998--2000
  Sorensen, 2005                                     Denmark                                      MI admission \<70 years                                        889        NR                     60                                   73%                                   NR                      1999--2000
  Nakatani, 2005                                      Japan                                             MI admission                                             2509      100%                    64                                   77%                                   NR                      1999--2003
  Costa Dias, 2005                                  Portugal                                           ACS admission                                             240        71%                    59                                   85%                                   NR                      2001--2002
  Bhattacharyya, 2007                                  UK                            ACS admission; 18 to 90 years with paid employment                          126        NR                     55                                   88%                                   85%                     2001--2004
  Parker, 2008                                      Australia                                          ACS admission                                             489        65%                    66                                   70%                                   NR                      2001--2003
  Wong, 2008                                           NZ                                              ACS admission                                             276        63%                    64                                   71%                                   NR                         2005

ACS = acute coronary syndrome; CAD = coronary artery disease; MI = myocardial infarction; NR = Not reported; NZ = New Zealand; UK = United Kingdom; USA = United States of America.

Provincial database with quarterly data evaluated from 2^nd^ quarter of 1993 to 1^st^ quarter of 2002.

Excluding 5 patients with "other" antidepressant use.

Based on 550 patient enrolled in the study at index hospitalization.

Based on 527 patients enrolled in study.

Based on 103 patients.

10.1371/journal.pone.0027671.t002

###### Antidepressant Prescription or Use in Included Studies.

![](pone.0027671.t002){#pone-0027671-t002-2}

  First Author, Year                                 Country     Method of Antidepressant Use Assessment   Time of Antidepressant Use Assessment   N (%) withAntidepressant                          Classes of AntidepressantsUsed
  ----------------------------------------------- ------------- ----------------------------------------- --------------------------------------- -------------------------- -------------------------------------------------------------------------------
  Benazon, 2005[a](#nt108){ref-type="table-fn"}      Canada              Administrative database                  Within 6 months post-MI            128--357 (8% to 16%)     [1993, Q2:]{.ul} SSRI = 29; TCA = 106. [2002, Q1:]{.ul} SSRI = 217; TCA = 126
  Grunau, 2006                                       Canada              Administrative database                  Within 12 months pre-MI                  471 (9%)                                                NR
  Lesperance, 2000                                   Canada                   Chart review                               Discharge                         18 (4%)                                                 NR
  Parakh, 2008                                         USA                    Chart review                               Discharge                         14 (5%)                                                 NR
  Sauer, 2001                                          USA                     Self-report                         Within 1 week pre-MI                    18 (3%)                                        SSRI = 13; Other = 5
  Lauzon, 2003                                       Canada                    Self-report                           12 months post-MI                     13 (3%)                                                 NR
  Grace, 2005                                        Canada                    Self-report                           During admission                      42 (5%)                                                 NR
  Rumsfeld, 2003                                       USA                    Chart review                               Discharge                        254 (13%)                                                NR
  Frasure-Smith, 2008                                Canada                Medicine containers                       2 months post-ACS                     68 (8%)                                                 NR
  Corser, 2006                                         USA                    Chart review                               Discharge                         61 (12%)                                                NR
  Mallik, 2006                                         USA                    Chart review                               Discharge                        231 (10%)                                                NR
  Grace, 2008                                        Canada                    Self-report                           9 months post-ACS                     48 (10%)                              SSRI = 27; TCA = 6; SNRI = 8; Other = 7
  Huffman, 2006                                        USA                    Chart review                           During admission                      16 (12%)                                                NR
  Zimmermann-Viehoff, 2010                           Sweden             Chart review/Self-report                     During admission                       0 (0%)                                                  0
  Monster, 2004                                      Denmark             Administrative database                   Within 90 days pre-MI                   540 (6%)                                      SSRI = 289; Other = 251
  Dickens, 2007                                        UK                     Chart review                               Discharge                         21 (4%)                                                 NR
  Kaptein, 2006                                    Netherlands                 Self-report                           3 months post-MI                      15 (3%)                                                 NR
  Pitzalis, 2001                                      Italy                    Self-report                           During admission                       0 (0%)                                                  0
  Sorensen, 2005                                     Denmark                  Chart review                               Discharge                         39 (4%)                                                 NR
  Nakatani, 2005                                      Japan             Chart review/Self-report                     During admission                      124 (5%)                                                NR
  Costa Dias, 2005                                  Portugal                   Self-report                          Prior to admission                      2 (1%)                                                 NR
  Bhattacharyya, 2007                                  UK                     Chart review                           During admission                       8 (6%)                                                 NR
  Parker, 2008                                      Australia                  Self-report                           During admission                      32 (7%)                                    SSRI = 17; TCA = 12; MAOI = 4
  Wong, 2008                                           NZ                      Self-report                           During admission                      11 (4%)                                                 NR

MAOI = monoamine oxidase inhibitor; NR = Not reported; NZ = New Zealand; Q1 = 1^st^ quarter; Q2 = 2^nd^ quarter; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant;

Provincial database with quarterly data evaluated from 2^nd^ quarter of 1993 to 1^st^ quarter of 2002.

Prevalence of Antidepressant Prescription or Use {#s3c}
------------------------------------------------

As shown in [Figure 2](#pone-0027671-g002){ref-type="fig"}, the rate of patients prescribed or using antidepressants increased from 1993 to 2005. [Results](#s3){ref-type="sec"} from the Benazon et al. study are shown separately for 9 cohorts/years (1993 to 2001) [@pone.0027671-Benazon1]. Generally, studies from North America reported substantially higher rates than studies from Europe. Based on self-report or chart review, the only study from North America from 1995 or earlier [@pone.0027671-Lesperance1] reported a rate of 4.2%, whereas the only pre-1995 European study, which reported on women under age 65 from Sweden, reported that no patients were using antidepressants upon admission for ACS [@pone.0027671-ZimmermannViehoff1]. One other study, which reported on Italian patients under the age of 70 admitted for MI from 1998 to 2000, similarly reported that no patients were using antidepressants at the time of admission [@pone.0027671-Pitzalis1]. Rates of antidepressant use or prescription among North American studies that used self-report or chart review from 2000 onward ranged from 9.5% to 13.0%, compared to 0.8% to 6.5% among non-North American studies in the same time period.

![Prevalence of Antidepressant Use in ACS Patients.\
Studies are grouped by geographic region and sorted by midpoint of data collection period. Benazon et al. [@pone.0027671-Benazon1] rates are denoted with grey markers. Error bars are +/−1.96 standard errors, and marker sizes are weighted according to the inverse of the squared standard error. \*Medication information was abstracted from patient charts but only prescriptions actually filled were included. ^†^Study reported, "only two patients were taking antidepressants prior to hospitalization," which was coded as being assessed at hospital admission.](pone.0027671.g002){#pone-0027671-g002}

Among studies of administrative databases, rates in North America ranged from 7.8% to 9.9% from 1993 to 1995 and increased to 13.8% to 14.8% in studies from 2000 onward. The only European study that used administrative data was a Danish study that reported a rate of 6.1% of 8,887 patients with antidepressant prescriptions in the years 1994 to 2002 [@pone.0027671-Monster1]. During approximately the same period, rates reported by Benazon et al. from Ontario, Canada increased from 7.8% in the second quarter of 1993 to 15.7% by the first quarter of 2002 (Benazon data in [Figure 2](#pone-0027671-g002){ref-type="fig"} through the second quarter of 2001) [@pone.0027671-Benazon1].

Only five studies reported rates of use or prescription by antidepressant class 28,35,42,45,53\], so analysis of rates by class was not possible. However, in the study by Benazon et al. [@pone.0027671-Benazon1] the percentage of patients prescribed an SSRI increased five-fold from approximately 2% in the second quarter of 1993 to approximately 10% in the first quarter of 2002. TCA prescription, on the other hand, remained stable at approximately 6% across the study period.

There were 17 studies that assessed prevalence of antidepressant prescription or use using non-administrative databases with study midpoints of October 1997 onward and were included in the meta-analysis, including 8 studies from North America [@pone.0027671-Lauzon1]--[@pone.0027671-Huffman1] and 9 studies from Europe [@pone.0027671-Dickens1]--[@pone.0027671-Sorensen1], [@pone.0027671-CostaDias1], [@pone.0027671-Bhattacharyya1], Japan [@pone.0027671-Nakatani1], Australia [@pone.0027671-Parker1], or New Zealand [@pone.0027671-Wong1]. Overall, the random effects model estimate for antidepressant use for all 17 studies was 6.1% (95% confidence interval (CI) 4.3% to 7.9%). However, the I^2^ statistic was extremely large (95.7%), indicating a substantial amount of between study heterogeneity, which was also seen in the funnel plot ([Figure 3](#pone-0027671-g003){ref-type="fig"}). Meta-regression was done with setting (North American versus Europe and other) and time (year of midpoint of data collection) as predictor variables. The estimated difference between rate of use in North America versus Europe and other was 5.1% (95% CI 2.5% to 7.8%, p\<0.001). In addition, the rate of use increased by approximately 0.5% per year (95% CI 0.0% to 1.1%, p = 0.065). Adjusting for setting and time accounted for 50% of heterogeneity in prevalence between studies from the overall meta-analysis, and the funnel plot reflected less structured heterogeneity and better model fit ([Figure 4](#pone-0027671-g004){ref-type="fig"}). [Results](#s3){ref-type="sec"} did not change if transformations of the raw proportions (arcsin and log) were modeled.

![Heterogeneity of Unadjusted Prevalence Estimates.\
The funnel plot shows individual study prevalence estimates (x-axis) plotted against estimated standard errors (y-axis). The white cone inside the gray region indicates a 95% probability region that points would be expected to fall into assuming no heterogeneity and no publication bias. The North American studies are indicated by the filled circles and the non-North American studies are indicated by the × symbols.](pone.0027671.g003){#pone-0027671-g003}

![Heterogeneity of Adjusted Prevalence Estimates.\
The funnel plot shows the residuals from the meta-regression on setting and time (x-axis) plotted against estimated standard errors (y-axis). The white cone inside the gray region indicates a 95% probability region that points would be expected to fall into assuming the assumptions of the meta-regression were valid. The North American studies are indicated by the filled circles and the other studies are indicated by the × symbols.](pone.0027671.g004){#pone-0027671-g004}

Discussion {#s4}
==========

Consistent with general population trends [@pone.0027671-Olfson1], [@pone.0027671-The1], [@pone.0027671-Mojtabai1] the prescription or use of antidepressants has risen dramatically among ACS patients since the early 1990s. Although there was substantial heterogeneity in results, overall, rates of antidepressant prescription or use increased from less than 5% prior to 1995 to 10--15% after 2000. One study that tracked antidepressant prescribing to post-MI patients using province-wide administrative data from Ontario, Canada found that the percentage of patients with an antidepressant prescription in the 6 months following hospital discharge increased from 7.8% in 1993 to 15.7% by 2002 [@pone.0027671-Benazon1]. In the meta-regression, there was an increase of approximately 0.5% per year in studies that used non-administrative data between 1997 and 2005. As with general population data, the rate of antidepressant prescription or self-reported use was notably higher in North America than in other parts of the world, primarily Europe, with an estimated difference of approximately 5.1% among studies from 1997 onward that used self-report or chart data to establish usage rates.

There has been a striking increase in the use of antidepressant medications in the general population in the past two decades, due in large part to a significant increase in the prescribing of antidepressant medications by nonpsychiatrists [@pone.0027671-Mojtabai1]. One reason for this trend is likely to be the perception that antidepressants are safe to use even in patients with medical comorbidities, including heart disease [@pone.0027671-Gill1]. Based on the results of several studies [@pone.0027671-Glassman2], [@pone.0027671-OConnor1], [@pone.0027671-Lesprance1] including post hoc analysis of the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) study [@pone.0027671-Taylor2], it has been concluded that SSRIs are safe to use in patients with heart disease [@pone.0027671-Lichtman1]. Consistent with this, a recent study of antidepressant use in primary care notes "...the preponderance of evidence suggests that it is not necessary to be overly cautious when prescribing for patients who have medical comorbidities. Most studies have demonstrated that SSRIs are safe and effective in persons who have both CAD (coronary artery disease) and stroke" [@pone.0027671-Gill1]. The side effects of the older antidepressants, however, limited their use in heart disease. TCAs can increase heart rate, produce orthostatic hypotension, decrease heart rate variability, prolong cardiac conduction, and trigger potentially lethal ventricular arrhythmias [@pone.0027671-Glassman2]. MAOIs can also produce orthostatic hypotension, but their potential to cause hypertensive crisis in patients who ingest tyramine-containing food or certain other drugs is the most concerning of their cardiovascular side effects [@pone.0027671-Blackwell1].

The increased use of antidepressant drugs in ACS patients in recent years may not only reflect greater comfort with these agents, but also a greater awareness of the burden of depression in patients with CHD [@pone.0027671-Thombs1], [@pone.0027671-vanMelle1]. Over the years, many informal calls have been made for increased depression treatment in heart disease patients, and recently an AHA Science Advisory recommended routine depression screening for all heart patients in order to increase the treatment rate [@pone.0027671-Lichtman1]. Indeed, the problem of under-diagnosed and under-treated depression has been recognized as an important public health issue outside of cardiovascular care settings, and increasing depression treatment, including antidepressant prescribing, has been prioritized [@pone.0027671-US2].

Whether depression in ACS patients is under-treated despite the more widespread prescription or use of antidepressants documented in this study is not known. Distinguishing under-use of antidepressants from appropriate use or overuse is beyond the scope of this systematic review. Nonetheless, it should be noted that overuse occurs when the risk of potential harm of using a drug outweighs the likely benefits for some patients. The overuse of antidepressants among populations who are unlikely to benefit meaningfully, is well-documented [@pone.0027671-Jureidini1]. In the context of ACS, it should be pointed out that as antidepressant use increases, the potential for harm, even if small, also increases. Although the SSRIs appear to have few direct adverse cardiovascular effects, clinically important drug-drug interactions may be encountered with more widespread use in ACS patients since many of these drugs inhibit hepatic cytochrome P450 isoenzymes [@pone.0027671-Spina1], which are involved in the metabolism of many cardiac drugs. The safety of SNRIs in ACS patients has not been as well-studied, which is important to consider since these drugs can increase blood pressure and heart rate [@pone.0027671-Stahl1]. It should be noted that recent reports raise persistent concern about potential adverse cardiovascular effects of antidepressant drugs [@pone.0027671-Pacher1], [@pone.0027671-US1], [@pone.0027671-Fosbol1], [@pone.0027671-Whang1], [@pone.0027671-Krantz1]--[@pone.0027671-Xiong1], suggesting that additional studies that evaluate cardiovascular side effects of antidepressant drugs in greater numbers of patients followed for longer time periods may be warranted.

There are limitations that should be considered in interpreting the results of this study. First, although the search that was conducted was broad and resulted in the review of more than 600 full-texts of articles, it is possible that some studies that reported on the rate of antidepressant use or prescription may not have been identified. Second, there are limitations in the methods used by original studies to ascertain the rate of antidepressant prescription or use. It is well-known, for instance, that self-report methods, which were used in a number of the studies we reviewed, tend to underestimate rates of prescription and use [@pone.0027671-Haapea1]--[@pone.0027671-Kwon1].

There were not enough studies from North America versus Europe and that used administrative data versus self-report or chart data across the time frame of the studies we reviewed to synthesize all data quantitatively. Thus, we were only able to estimate the prevalence quantitatively using non-administrative database studies that were conducted from 1997 onward. With only 17 studies included in the meta-analysis and limited information on some of these, we were not able to adjust for study characteristics beyond setting and time, such as patient gender or age. Even after adjusting for these variables, there was a substantial amount of heterogeneity between studies. Thus, the meta-regression results should be interpreted with caution.

Additionally, very few studies provided information on the classes of antidepressants prescribed, which did not permit specific analysis. Furthermore, no studies with data on antidepressant prescription or use since 2005 were available, so it is not known whether or not prescription rates have continued to increase beyond the rates reported in the studies reviewed. Finally, the protocol for this review was not registered prior to initiating work on the review.

In summary, the results of this systematic review showed that the rate of antidepressant prescriptions and use has risen dramatically in recent years among ACS patients and, as in the general population, tends to be higher in North America than in other parts of the world. The fact that by 2005 between 10% and 15% of ACS patients were prescribed or using an antidepressant suggests that more patients are receiving treatment for depression, which is clearly an important problem in patients with heart disease. Alternatively, this prevalence of antidepressant use raises the possibility that antidepressants are being used by some ACS patients who may not benefit meaningfully despite being exposed to the possibility of adverse effects of the drugs themselves or to clinically significant drug-drug interactions. Careful consideration needs to be given to the balance between potential benefits and harms in prescribing antidepressant medications to patients with heart disease.
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